List of Excipients in Branded Drug ALTOPREV

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	ACETYLTRIBUTYL CITRATE
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	BUTYLATED HYDROXYANISOLE
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	CANDELILLA WAX
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	CELLULOSE ACETATE
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	FD&C YELLOW NO. 6
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	FERRIC OXIDE RED
Covis Pharma US Inc	ALTOPREV	lovastatin	70515-628	FERROSOFERRIC OXIDE

Altoprev Excipient Strategy and Commercial Opportunities for Lovastatin Extended-Release Tablets

Last updated: August 8, 2026

Altoprev is the former brand for lovastatin extended-release tablets, developed to provide once-daily cholesterol treatment through a modified-release oral solid dosage form. Its commercial opportunity is now limited as a standalone brand because immediate-release lovastatin is generic, statin competition is intense, and Altoprev is no longer actively marketed in the United States. The strongest remaining opportunities are a low-cost generic or 505(b)(2) extended-release product, excipient-enabled reformulation, regional licensing, and use of the underlying delivery technology in other poorly soluble compounds.

What is Altoprev and how was it formulated?

Altoprev contains lovastatin, an HMG-CoA reductase inhibitor used to reduce elevated total cholesterol and low-density lipoprotein cholesterol. Unlike conventional lovastatin tablets, Altoprev was designed as an extended-release product for once-daily administration.

The FDA-approved strengths were 20 mg, 40 mg, and 60 mg extended-release tablets. The product used a hydrophilic matrix approach in which the drug was incorporated into a polymer-containing tablet system that controlled water penetration, matrix swelling, drug dissolution, and gastrointestinal release [1].

The formulation’s commercial rationale was based on two attributes:

1. Longer drug release over the gastrointestinal transit period.
2. A dosing profile differentiated from conventional immediate-release lovastatin.

Altoprev was approved under NDA 021366. The product is listed by FDA as discontinued, and its original U.S. commercial positioning has largely disappeared from the active lipid-lowering market [2].

What excipients were used in Altoprev?

Public FDA labeling identifies inactive ingredients associated with the extended-release tablet, including excipients commonly used in hydrophilic matrix systems and film-coated oral tablets. The formulation platform included matrix-forming, binding, disintegrating, lubricating, and coating components.

Excipient function	Likely formulation role in Altoprev-type tablets
Hypromellose	Hydrophilic matrix former and release-controlling polymer
Lactose monohydrate	Diluent and tablet-volume contributor
Microcrystalline cellulose	Diluent, compression aid, and tablet-strength enhancer
Povidone	Binder and granulation aid
Crospovidone	Disintegration support outside the controlled-release matrix
Colloidal silicon dioxide	Glidant and powder-flow aid
Magnesium stearate	Lubricant
Talc and coating materials	Film-coating performance, appearance, and handling

The precise quantitative composition is not fully disclosed in the public label. A commercial development program would therefore need to reproduce the release profile through comparative formulation work rather than rely solely on qualitative excipient matching.

What excipient strategy is most suitable for an Altoprev generic?

A generic Altoprev strategy should prioritize dissolution-profile control, manufacturing robustness, and regulatory comparability rather than novel excipient selection. The highest-value excipients are those that determine drug release across pH conditions and agitation rates.

Hydrophilic matrix polymers

Hypromellose is the most logical starting polymer because it is widely accepted in modified-release oral dosage forms and offers multiple viscosity grades. Higher-viscosity grades generally produce stronger gel layers and slower release. Lower-viscosity grades can improve manufacturability and reduce the risk of incomplete release.

Potential alternatives include:

• Polyethylene oxide for stronger swelling and erosion control.
• Hydroxypropyl cellulose for matrix formation and binder functionality.
• Carbomers for high-viscosity release control, subject to compatibility and processing constraints.
• Ethylcellulose in a multiparticulate or coated-particle design.

A direct-copy strategy would normally favor hypromellose because it reduces regulatory complexity and preserves a familiar excipient platform. A differentiated formulation could use an insoluble polymer coating or multiparticulate system, but that would increase development cost and bioequivalence risk.

Solubility and wetting control

Lovastatin is poorly water-soluble. The formulation must balance solubilization against excessive release acceleration. Useful tools include:

• Surfactants such as sodium lauryl sulfate or poloxamers.
• Wetting agents.
• Particle-size reduction.
• Amorphous solid dispersion approaches.
• Lipid-based granulation or self-emulsifying systems.

These approaches can improve dissolution but may undermine extended release. A solubility-enhancing excipient should therefore be evaluated within the matrix, not as an isolated dissolution intervention.

Compression and granulation excipients

Lovastatin extended-release tablets require adequate mechanical strength while maintaining reproducible porosity. Microcrystalline cellulose, lactose, povidone, and colloidal silicon dioxide are commercially practical choices.

Direct compression may reduce processing steps, but wet granulation can improve content uniformity and control polymer distribution. The preferred process depends on drug loading, flow behavior, moisture sensitivity, and the selected polymer grade.

Lubricant control

Magnesium stearate concentration and blending time require tight control. Excessive lubrication can reduce tablet wettability, weaken interparticle bonding, and alter the release rate. This is particularly important in a hydrophilic matrix where water penetration determines polymer hydration.

What formulation patents protected Altoprev?

Altoprev was based on extended-release formulation technology rather than a new lovastatin molecule. Any original formulation patents would have focused on matrix composition, release characteristics, dosage strengths, or manufacturing methods.

The practical protection position has changed materially because:

• Lovastatin’s compound patent protection expired years ago.
• The product was approved in 2002, placing any ordinary U.S. formulation patent terms near or beyond the current period unless patent-term adjustment or extension materially changed the date.
• The product is no longer an active commercial brand.
• The economic value of old formulation patents is reduced by the availability of immediate-release lovastatin and alternative statins.

An applicant assessing freedom to operate should review the FDA Orange Book historical listings, the USPTO patent file, continuation applications, terminal disclaimers, and litigation records. The Orange Book is the controlling source for patents listed against an approved drug product, but historical listings should be examined because older patents may no longer appear in the current active listing [3].

Are there active Orange Book patents for Altoprev?

Altoprev does not represent a meaningful current Orange Book exclusivity barrier in the U.S. The key commercial issue is not an active brand patent blocking entry. It is whether a new extended-release lovastatin formulation can satisfy FDA requirements for pharmaceutical equivalence or obtain approval through a 505(b)(2) pathway.

A developer should distinguish between:

• A generic ANDA referencing the discontinued extended-release product.
• A 505(b)(2) application using published data or FDA findings for lovastatin.
• A new drug application supported by a new clinical or pharmacokinetic package.

The pathway depends on whether a suitable reference listed drug remains available and whether the proposed product is sufficiently similar in dosage form, release mechanism, strength, and labeling.

When did Altoprev lose exclusivity?

Altoprev’s meaningful U.S. market exclusivity has expired. The product’s approval in 2002 means its five-year new chemical entity exclusivity period ended in approximately 2007, although Altoprev was not a new chemical entity because lovastatin had already been approved in immediate-release products. Any three-year exclusivity associated with a new clinical investigation would also have expired long ago.

The product’s commercial protection was therefore based primarily on formulation patents and brand differentiation. Those protections no longer support a substantial premium market.

Protection category	Altoprev position
Active ingredient	Expired
New chemical entity exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance
Formulation patents	Historical; no material current barrier identified
Orange Book exclusivity	No meaningful current exclusivity
Brand commercialization	Discontinued or inactive in the U.S.
Generic substitution opportunity	Technically possible, commercially limited

What FDA regulatory pathway applies to a new Altoprev-like product?

A new sponsor would likely evaluate an ANDA first, but the pathway may be complicated by the product’s discontinued commercial status and the availability of an appropriate reference product.

ANDA strategy

An ANDA could be attractive if FDA recognizes an eligible reference listed drug and the proposed product can demonstrate pharmaceutical equivalence and bioequivalence. The formulation would need to match the reference in dosage form, strength, route, and release characteristics.

For a modified-release product, the bioequivalence package may require:

• Single-dose fasting study.
• Single-dose fed study.
• Steady-state study if applicable.
• Partial or full replicate design.
• Comparative dissolution under multiple pH and agitation conditions.
• Food-effect characterization.

505(b)(2) strategy

A 505(b)(2) application may be more flexible if the proposed product changes:

• Release mechanism.
• Dosing frequency.
• Tablet size.
• Excipient system.
• Food-effect profile.
• Pharmacokinetic exposure.
• Labeling or administration instructions.

The 505(b)(2) route can support a differentiated product, but it usually requires a stronger clinical and regulatory package than a conventional ANDA. The sponsor must also address listed patents and exclusivity if any remain relevant to the referenced product.

What commercial opportunities exist for Altoprev excipients?

The highest-value commercial opportunities are not likely to come from relaunching the Altoprev brand. They are more likely to arise from excipient and platform applications.

1. Generic extended-release lovastatin

A manufacturer could pursue an inexpensive extended-release lovastatin product for markets where once-daily modified release retains clinical or payer value. The product would face immediate-release lovastatin generics and stronger competitors such as atorvastatin, simvastatin, rosuvastatin, and pravastatin.

The product would need a clear advantage, such as:

• Lower manufacturing cost.
• Improved tolerability or adherence.
• More convenient dosing.
• Better food-effect control.
• Regional formulary positioning.
• Reliable supply in markets with limited statin competition.

2. Excipient platform licensing

The matrix technology used for Altoprev-like products could be licensed for other poorly soluble oral drugs. The platform would be more valuable if it can demonstrate:

• Reproducible extended release.
• Low sensitivity to polymer grade variation.
• Robust dissolution across pH conditions.
• Scale-up from laboratory to commercial batch size.
• Compatibility with direct compression.
• Reduced food-effect variability.

Excipient suppliers can commercialize premixes containing a matrix polymer, filler, binder, glidant, and lubricant. Premixed systems reduce development time for generic manufacturers and may create recurring volume sales even when the finished drug has low margins.

3. Reformulated statin products

A sponsor could use a modified-release platform to develop combination products involving lovastatin or other lipid-lowering agents. Potential combinations might include a statin with ezetimibe, antihypertensive therapy, or diabetes treatment.

The commercial case would depend on clinical differentiation and reimbursement. A reformulation without improved adherence, tolerability, or outcomes would have limited pricing power.

4. Regional licensing

Markets with established use of lovastatin but limited access to advanced statin products may offer a modest opportunity. Licensing could focus on:

• Latin America.
• Selected Asian markets.
• Middle-income markets with local manufacturing.
• Territories where modified-release products have limited competition.

The principal barriers are local registration requirements, patent term differences, reference-product availability, and price competition from immediate-release lovastatin.

How strong is the Altoprev patent estate?

The Altoprev patent estate is weak as a current commercial asset. Its original value came from formulation differentiation, but the product’s age, discontinuation, and competition from generic statins reduce enforcement and licensing value.

Patent-estate factor	Assessment
Molecule protection	None of practical value
Formulation protection	Historical and likely expired or commercially immaterial
Manufacturing protection	Potentially narrow and design-aroundable
Method-of-use protection	Limited because statin indications are established
Biosimilar protection	Not applicable
Generic blocking power	Low
Licensing value	Concentrated in know-how and platform transfer
Litigation leverage	Low absent a newly issued or unexpired patent

The most defensible intellectual property for a new product would come from a genuinely differentiated formulation, such as a specific polymer ratio, multiparticulate architecture, food-effect reduction, or manufacturing process that produces a clinically relevant release profile.

Which companies could challenge or commercialize an Altoprev-like product?

The relevant competitive set includes generic manufacturers with modified-release oral solid-dose capabilities. Potential participants include large generic companies and contract development and manufacturing organizations with expertise in matrix tablets.

A commercial entrant would compete against:

• Generic lovastatin immediate-release manufacturers.
• Authorized or branded statin products.
• Atorvastatin and simvastatin suppliers.
• Rosuvastatin manufacturers.
• Fixed-dose lipid-lowering combinations.
• Digital adherence and chronic-care programs that reduce the perceived value of modified release.

No major biosimilar risk exists because lovastatin is a small-molecule drug. The competitive risk is generic substitution and therapeutic substitution, not biologic interchangeability.

What generic launch scenarios exist for Altoprev?

Three launch scenarios are commercially relevant.

Low-cost ANDA launch

This is the least expensive path if FDA accepts a suitable reference product. The entrant would compete primarily on price and supply reliability. Margins would likely be thin.

Differentiated 505(b)(2) launch

A sponsor could pursue a new extended-release formulation with improved food-effect behavior or a more convenient dosage form. This could support a branded or authorized-generic strategy, but development cost and regulatory risk would be higher.

Excipient-platform licensing

A technology owner could avoid finished-dose competition by licensing the matrix system to multiple drug developers. This approach provides broader application potential and reduces exposure to the declining lovastatin market.

What revenue exposure does Altoprev represent?

Altoprev itself has limited current revenue exposure because the brand is no longer a major marketed U.S. product. The relevant revenue opportunity is incremental revenue from a replacement product or licensed formulation technology.

A financial model should use a conservative framework:

Revenue driver	Expected impact
U.S. branded lovastatin sales	Low
U.S. generic extended-release sales	Low to moderate, dependent on reference-product status
Immediate-release generic substitution	Strong negative factor
International sales	Market-specific and potentially modest
Excipient premix sales	Moderate platform opportunity
Licensing revenue	Potentially higher than finished-product revenue if multiple applications succeed
Combination-product opportunity	Higher upside but higher clinical and regulatory cost

Key Takeaways

• Altoprev is a discontinued lovastatin extended-release product with no meaningful remaining brand exclusivity.
• Its formulation strategy relied on a hydrophilic matrix tablet using conventional pharmaceutical excipients, including hypromellose, lactose, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, and magnesium stearate.
• A direct generic would face substantial competition from immediate-release lovastatin and other statins.
• The strongest commercial opportunity is an excipient or modified-release platform, not a standalone Altoprev relaunch.
• A 505(b)(2) product would need measurable differentiation, such as improved food-effect control, adherence, or pharmacokinetic performance.
• No biosimilar issue applies. The principal threats are generic substitution, therapeutic substitution, and low pricing.
• Any new investment should focus on formulation know-how, excipient premixes, and cross-molecule licensing rather than historical Altoprev patent rights.

FAQs About Altoprev Excipient and Commercial Strategy

What is the main release-controlling excipient in Altoprev?

Hypromellose is the principal release-controlling polymer associated with the hydrophilic matrix approach used for Altoprev-type extended-release tablets.

Can Altoprev be reformulated as a once-daily generic?

A once-daily generic may be possible, but the sponsor would need to establish the applicable FDA pathway, identify an eligible reference product, and demonstrate modified-release bioequivalence.

Is lovastatin still commercially attractive?

Lovastatin has limited standalone commercial attractiveness because multiple statins are generic and clinicians commonly use atorvastatin or rosuvastatin. Lovastatin becomes more attractive when paired with a differentiated delivery system or combination product.

Are Altoprev excipients suitable for other drugs?

Yes. Hydrophilic matrix excipients such as hypromellose, microcrystalline cellulose, povidone, and silica are broadly used in oral modified-release development. Their value depends on achieving reproducible release for the target active ingredient.

Does Altoprev have biosimilar competition?

No. Lovastatin is a chemically synthesized small molecule. Competition comes from generic drugs and therapeutic alternatives, not biosimilars.

References

1. U.S. Food and Drug Administration. (2002). Altoprev (lovastatin) extended-release tablets prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Altoprev, NDA 021366.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. U.S. Food and Drug Administration. (2013). Inactive ingredients in approved drug products database.
5. U.S. Food and Drug Administration. (2019). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.